萬孚生物(300482.SZ)2020年度權益分派10轉3派5元 股權登記日為5月25日
格隆匯5月18日丨萬孚生物(300482.SZ)發佈2020年年度權益分派實施公吿,以此次權益分派股權登記日2021年5月25日收市後的總股本,剔除因公司通過集中競價交易方式回購的、依法不參與利潤分配的1,020,410股之後的股本總額為基數,向全體股東每10股派5元人民幣現金(含税),同時,以資本公積金向全體股東每10股轉增3股。
此次權益分派股權登記日為2021年5月25日,除權除息日為2021年5月26日,此次所送(轉)的無限售條件流通股的起始交易日為2021年5月26日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.